Clear Search sequence regions

  • adult (1)
  • cervix cancer (1)
  • drug- effects (1)
  • female (1)
  • gardasil (5)
  • human (4)
  • Quadrivalent (2)
  • women (1)
  • young adult (1)
  • Sizes of these terms reflect their relevance to your search.

    A trial of 14,215 women aged between 16 and 26 years comparing a new vaccine with nine human papilloma virus types - four from the licensed Gardasil vaccine (types 6, 11,16 and 18) and five new ones (types 31, 33, 45, 52 and 58) to Gardasil - has shown improved protection against cervical cancer precursor lesions. Antibody response for the four original Gardasil types was not inferior and a 96.3% reduction in high-grade cervical disease for the other five types not in Gardasil was seen in the per-protocol population. Six-month persistent infection was reduced by 96% for these types. There were no serious safety concerns, although injection site reactions were more common with the new vaccine.


    Jack Cuzick. Gardasil 9 joins the fight against cervix cancer. Expert review of vaccines. 2015;14(8):1047-9

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 26028344

    View Full Text